Tuoxin Pharmaceutical announced that its wholly-owned subsidiary Xinxiang Pharmaceutical Co., Ltd. obtained the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” issued by the State Drug Administration. The approval conclusion was that it met the requirements relating to drug registration and approved for registration. After completing the GMP compliance check, the API will be qualified for production and sales in the domestic market.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.